Supernus Pharmaceuticals (SUPN) Work In Process (2013 - 2026)

Supernus Pharmaceuticals (SUPN) has 14 years of Work In Process data on file, last reported at $36.1 million in Q1 2026.

• Work In Process for Q1 2026 came in at $36.1 million, up 92.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.1 million (up 92.85% YoY), and the FY2025 annual result was $29.4 million, up 10.14% from the prior year.
• Work In Process grew to $36.1 million in Q1 2026 per SUPN's latest filing, from $29.4 million in the prior quarter.
• Over five years, Work In Process peaked at $46.2 million in Q1 2022 and troughed at $15.6 million in Q2 2025.
• A 5-year average of $28.9 million and a median of $28.1 million in 2024 frame the typical range for Work In Process.
• The sharpest annual moves came in 2022 and 2023: Work In Process jumped 395.38% in 2022, then slumped 36.0% in 2023.
• A 5-year view of Work In Process shows it stood at $31.7 million in 2022, then retreated by 1.57% to $31.2 million in 2023, then retreated by 14.38% to $26.7 million in 2024, then grew by 10.14% to $29.4 million in 2025, then increased by 22.48% to $36.1 million in 2026.
• Business Quant data shows SUPN's Work In Process at $36.1 million in Q1 2026, $29.4 million in Q4 2025, and $33.4 million in Q3 2025.